TT125-802

N/A

Report date: 2026/04/13 20:02:18
NME

Base Information

Drug NameTT125-802
Drug Alias NameTT125-802TT-125-802TT-125TT125
ClassificationSmall molecules
Mechanisms of Actionp300-CBP transcription factors inhibitors
Targetsp300-CBP transcription factors
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsHematologic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandSpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTolremo Therapeutics AG
China Registration ClassN/A

Develop Information

Active CompaniesTolremo Therapeutics AG
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsHematologic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A